While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

The best metric is not weight, but a particularly toxic kind of fat.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

President Donald Trump signed an executive order that claims to force Big Medicine to lower prescription drug prices paid by ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...